VOYAGER THERAPEUTICS INC (VYGR) Stock Price, Quote, News and Overview
NASDAQ:VYGR - Nasdaq - US92915B1061 - Common Stock - Currency: USD
VYGR Quote, Performance and Key Statistics
4.15
+0.19 (+4.8%)
The current stock price of VYGR is 4.15 USD. In the past month the price decreased by -25.7%. In the past year, price decreased by -57.74%.
VYGR Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.9 | 373.82B | ||
| AMGN | AMGEN INC | 15.97 | 170.00B | ||
| GILD | GILEAD SCIENCES INC | 25.04 | 143.84B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1695.31 | 126.30B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.06 | 75.12B | ||
| ARGX | ARGENX SE - ADR | 247.66 | 38.67B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.15B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.98B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.51B | ||
| BIIB | BIOGEN INC | 8.73 | 20.95B | ||
| NTRA | NATERA INC | N/A | 19.53B | ||
| GMAB | GENMAB A/S -SP ADR | 25.64 | 15.31B |
Related stock screener links
About VYGR
Company Profile
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. The company is headquartered in Lexington, Massachusetts and currently employs 162 full-time employees. The company went IPO on 2015-11-11. The Company’s pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of its programs are derived from its TRACER AAV capsid discovery platform, which is used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs, all of which are in preclinical development, include Anti-Tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy Program, Tau Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program, and others. VY-TAU01 is for the treatment of Alzheimer’s disease. SOD1 Silencing Gene Therapy Program is for the treatment of ALS.
Company Info
VOYAGER THERAPEUTICS INC
75 Hayden Avenue
Lexington MASSACHUSETTS 02139 US
CEO: G. Andre Turenne
Employees: 162
Company Website: https://www.voyagertherapeutics.com/
Investor Relations: https://ir.voyagertherapeutics.com/
Phone: 18572595340
VOYAGER THERAPEUTICS INC / VYGR FAQ
What is the stock price of VOYAGER THERAPEUTICS INC today?
The current stock price of VYGR is 4.15 USD. The price increased by 4.8% in the last trading session.
What is the ticker symbol for VOYAGER THERAPEUTICS INC stock?
The exchange symbol of VOYAGER THERAPEUTICS INC is VYGR and it is listed on the Nasdaq exchange.
On which exchange is VYGR stock listed?
VYGR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for VOYAGER THERAPEUTICS INC stock?
18 analysts have analysed VYGR and the average price target is 17.03 USD. This implies a price increase of 310.46% is expected in the next year compared to the current price of 4.15. Check the VOYAGER THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is VOYAGER THERAPEUTICS INC worth?
VOYAGER THERAPEUTICS INC (VYGR) has a market capitalization of 226.71M USD. This makes VYGR a Micro Cap stock.
How many employees does VOYAGER THERAPEUTICS INC have?
VOYAGER THERAPEUTICS INC (VYGR) currently has 162 employees.
What are the support and resistance levels for VOYAGER THERAPEUTICS INC (VYGR) stock?
VOYAGER THERAPEUTICS INC (VYGR) has a resistance level at 4.11. Check the full technical report for a detailed analysis of VYGR support and resistance levels.
Is VOYAGER THERAPEUTICS INC (VYGR) expected to grow?
The Revenue of VOYAGER THERAPEUTICS INC (VYGR) is expected to decline by -45.77% in the next year. Check the estimates tab for more information on the VYGR EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy VOYAGER THERAPEUTICS INC (VYGR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of VYGR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of VYGR, evaluating the profitability, health, valuation and growth aspects
- VOYAGER THERAPEUTICS INC (VYGR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- VOYAGER THERAPEUTICS INC (VYGR) Sales and EPS estimates to see what analysts future expectations are.
- VOYAGER THERAPEUTICS INC (VYGR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- VOYAGER THERAPEUTICS INC (VYGR) Insider and Institutional Ownership to learn about the owners and their transactions.
- VOYAGER THERAPEUTICS INC (VYGR) Stock Chart to make your own analysis
- VOYAGER THERAPEUTICS INC (VYGR) Latest news and press-releases to stay up to date.
Does VOYAGER THERAPEUTICS INC (VYGR) stock pay dividends?
VYGR does not pay a dividend.
When does VOYAGER THERAPEUTICS INC (VYGR) report earnings?
VOYAGER THERAPEUTICS INC (VYGR) will report earnings on 2025-03-11, after the market close.
What is the Price/Earnings (PE) ratio of VOYAGER THERAPEUTICS INC (VYGR)?
The PE ratio for VOYAGER THERAPEUTICS INC (VYGR) is 5.85. This is based on the reported non-GAAP earnings per share of 0.71 and the current share price of 4.15 USD. Check the full fundamental report for a full analysis of the valuation metrics for VYGR.
What is the Short Interest ratio of VOYAGER THERAPEUTICS INC (VYGR) stock?
The outstanding short interest for VOYAGER THERAPEUTICS INC (VYGR) is 5.99% of its float. Check the ownership tab for more information on the VYGR short interest.
VYGR Technical Analysis
VYGR Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to VYGR. VYGR is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
VYGR Financial Highlights
Over the last trailing twelve months VYGR reported a non-GAAP Earnings per Share(EPS) of 0.71. The EPS decreased by -42.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 15.8% | ||
| ROA | 6.07% | ||
| ROE | 7.84% | ||
| Debt/Equity | 0 |
VYGR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 88% to VYGR. The Buy consensus is the average rating of analysts ratings from 18 analysts.
For the next year, analysts expect an EPS growth of -130.5% and a revenue growth -45.77% for VYGR